These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34060810)

  • 1. Nanomechanical Phenotypes in Cardiac Myosin-Binding Protein C Mutants That Cause Hypertrophic Cardiomyopathy.
    Suay-Corredera C; Pricolo MR; Velázquez-Carreras D; Pathak D; Nandwani N; Pimenta-Lopes C; Sánchez-Ortiz D; Urrutia-Irazabal I; Vilches S; Dominguez F; Frisso G; Monserrat L; García-Pavía P; de Sancho D; Spudich JA; Ruppel KM; Herrero-Galán E; Alegre-Cebollada J
    ACS Nano; 2021 Jun; 15(6):10203-10216. PubMed ID: 34060810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
    Smelter DF; de Lange WJ; Cai W; Ge Y; Ralphe JC
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1179-H1191. PubMed ID: 29451820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.
    Suay-Corredera C; Alegre-Cebollada J
    FEBS Lett; 2022 Mar; 596(6):703-746. PubMed ID: 35224729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction.
    De Lange WJ; Grimes AC; Hegge LF; Spring AM; Brost TM; Ralphe JC
    J Gen Physiol; 2013 Sep; 142(3):241-55. PubMed ID: 23980194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
    Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
    J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy.
    Suay-Corredera C; Pricolo MR; Herrero-Galán E; Velázquez-Carreras D; Sánchez-Ortiz D; García-Giustiniani D; Delgado J; Galano-Frutos JJ; García-Cebollada H; Vilches S; Domínguez F; Molina MS; Barriales-Villa R; Frisso G; Sancho J; Serrano L; García-Pavía P; Monserrat L; Alegre-Cebollada J
    J Biol Chem; 2021 Jul; 297(1):100854. PubMed ID: 34097875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
    Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
    Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes.
    Flavigny J; Souchet M; Sébillon P; Berrebi-Bertrand I; Hainque B; Mallet A; Bril A; Schwartz K; Carrier L
    J Mol Biol; 1999 Nov; 294(2):443-56. PubMed ID: 10610770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position.
    Mun JY; Kensler RW; Harris SP; Craig R
    J Mol Cell Cardiol; 2016 Feb; 91():141-7. PubMed ID: 26718724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.
    van Dijk SJ; Bezold Kooiker K; Mazzalupo S; Yang Y; Kostyukova AS; Mustacich DJ; Hoye ER; Stern JA; Kittleson MD; Harris SP
    Arch Biochem Biophys; 2016 Jul; 601():133-40. PubMed ID: 26777460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
    Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
    J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
    O'Leary TS; Snyder J; Sadayappan S; Day SM; Previs MJ
    J Mol Cell Cardiol; 2019 Feb; 127():165-173. PubMed ID: 30550750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study.
    Krishnamoorthy N; Gajendrarao P; Olivotto I; Yacoub M
    J Biomol Struct Dyn; 2017 Jul; 35(9):1916-1922. PubMed ID: 27267291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
    Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
    J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities.
    Schlossarek S; Mearini G; Carrier L
    J Mol Cell Cardiol; 2011 Apr; 50(4):613-20. PubMed ID: 21291890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
    van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
    Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament.
    Harris SP; Lyons RG; Bezold KL
    Circ Res; 2011 Mar; 108(6):751-64. PubMed ID: 21415409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural characterization of the C3 domain of cardiac myosin binding protein C and its hypertrophic cardiomyopathy-related R502W mutant.
    Zhang XL; De S; McIntosh LP; Paetzel M
    Biochemistry; 2014 Aug; 53(32):5332-42. PubMed ID: 25058872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablation of cardiac myosin-binding protein-C accelerates contractile kinetics in engineered cardiac tissue.
    de Lange WJ; Grimes AC; Hegge LF; Ralphe JC
    J Gen Physiol; 2013 Jan; 141(1):73-84. PubMed ID: 23277475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac myosin-binding protein C: hypertrophic cardiomyopathy mutations and structure-function relationships.
    Sequeira V; Witjas-Paalberends ER; Kuster DW; van der Velden J
    Pflugers Arch; 2014 Feb; 466(2):201-6. PubMed ID: 24240729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.